I am writing in relation to the new drug comment about romosozumab (Evenity),1 published in Australian Prescriber. There is no mention that when treatment with romosozumab is completed transition to an antiresorptive therapy is required to preserve bone mass, as recommended in the Australian approved product information. This states, ‘After completing Evenity therapy, transition
to an antiresorptive osteoporosis therapy is required to preserve bone mass.’ I bring this to the attention of your readers in the interest of the quality use of medicines.
Jeffrey Hassall
Senior Medical Advisor, Amgen Australia, Sydney
Conflicts of interest: Jeffrey Hassall is employed by Amgen Australia and has stock/stock options in Amgen Inc.
